15160 - ISTH "Combining Antiplatelet and Anticoagulant Therapy"
Through its educational arm, the ISTH Academy, the International Society on Thrombosis and Haemostasis (ISTH) has begun hosting a series of webinars on practical thrombosis and haemostasis issues that scientists and physicians frequently confront. These webinars will allot time for participants to ask questions and will cover the latest information on relevant topics.
Moderated by: Raj Kasthuri
John Eikelboom, MD - Topic: Combining antiplatelet therapy with anticoagulants
Laura Mauri, MD - Topic: Dual Anti-platelet Therapy: Current management strategies following cardiac stent placement
Accreditation Statement
Target Audience
Presentation is attended for basic scientists and clinicians, including trainees, interested in antiplatelet and anticoagulant therapy.
Learning Objectives
At the conclusion of this activity, I will be able to:
- Describe the rationale for combining antiplatelet and anticoagulant therapy
- Differentiate between the clinical settings in which the combination is of proven and unproven benefit
- Justify the implications of the currently available evidence for clinical practice and future research
- Understand new developments in coronary device and concomitant pharmacologic strategies to prevent ischemic complications in patients treated with coronary stents
- Understand results from recent clinical trials regarding antiplatelet therapy in patients treated with coronary stents
- Identify examples of observational data and randomized trial analysis as methods to compare treatment strategies
Moderated by: Raj Kasthuri
All persons in control of content have NO relevant financial relationships to disclose with the exception of the following persons:
Name | Company | Role |
Chris Ward, MD | Bayer | Advisory Board, Speaker |
Pfizer, BMS | Advisory Board, Speaker | |
Boehringer-Ingelheim | Advisory Board, Speaker | |
Alexion | Advisory Board | |
Medimark | Steering Committee Member, Speaker | |
Geoff Barnes | BMS, Pfizer, Blue Cross Blue Shield of Michigan | Primary Investigator & Co-Investigator |
Yukio Ozaki | Sysmex | Advisory Board |
Raj Kasthuri | Bayer Healthcare, GSK | Consultant |
John Eikelboom | Astra-Zeneca, Bayer, BMS, Pfizer, Janssen, Sanofi-Aventis, Eli-Lilly, Boehringer-Ingelheim, Daiichi, GSK | Consultant |
Laura Mauri | Abbott, Boston Scientific, Cordis, Medtronic Eli Lilly, Daiichi Sankyo, BMS, Sanofi-Aventis, Biotronik, Medtronic, St. Jude Medical | PI, Consultant |
In accordance with the ACCME® Standards for Commercial Support Number 6, all in control of content disclosed any relevant financial relationships. These relationships were reviewed via the MCW conflict of interest resolution process and resolved
Available Credit
- 1.00 AMA PRA Category 1 Credit(s)™AMA PRA Category 1 Credit(s)™
- 1.00 Hours of ParticipationHours of Participation credit.
Price
Required Hardware/software
To view the webcast on your computer go to https://www.isth.org/ click the Events/Webinars tab and view the ISTH 2015 Archived Webinars